These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35964620)

  • 1. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.
    Kleppe A; Skrede OJ; De Raedt S; Hveem TS; Askautrud HA; Jacobsen JE; Church DN; Nesbakken A; Shepherd NA; Novelli M; Kerr R; Liestøl K; Kerr DJ; Danielsen HE
    Lancet Oncol; 2022 Sep; 23(9):1221-1232. PubMed ID: 35964620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
    Skrede OJ; De Raedt S; Kleppe A; Hveem TS; Liestøl K; Maddison J; Askautrud HA; Pradhan M; Nesheim JA; Albregtsen F; Farstad IN; Domingo E; Church DN; Nesbakken A; Shepherd NA; Tomlinson I; Kerr R; Novelli M; Kerr DJ; Danielsen HE
    Lancet; 2020 Feb; 395(10221):350-360. PubMed ID: 32007170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
    Li X; Jonnagaddala J; Yang S; Zhang H; Xu XS
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1955-1963. PubMed ID: 35332389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
    Frei AL; McGuigan A; Sinha RRAK; Jabbar F; Gneo L; Tomasevic T; Harkin A; Iveson T; Saunders MP; Oien KA; Maka N; Pezzella F; Campo L; Browne M; Glaire M; Kildal W; Danielsen HE; Hay J; Edwards J; Sansom O; Kelly C; Tomlinson I; Kerr R; Kerr D; Domingo E; ; Church DN; Koelzer VH
    Lancet Oncol; 2024 Feb; 25(2):198-211. PubMed ID: 38301689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatin organisation and cancer prognosis: a pan-cancer study.
    Kleppe A; Albregtsen F; Vlatkovic L; Pradhan M; Nielsen B; Hveem TS; Askautrud HA; Kristensen GB; Nesbakken A; Trovik J; Wæhre H; Tomlinson I; Shepherd NA; Novelli M; Kerr DJ; Danielsen HE
    Lancet Oncol; 2018 Mar; 19(3):356-369. PubMed ID: 29402700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
    Kenseth A; Kantorova D; Seo MK; Aas E; Cairns J; Kerr D; Askautrud H; Jacobsen JE
    Pharmacoeconomics; 2024 Jun; 42(6):679-691. PubMed ID: 38584239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated assessment of CD8
    Jiang D; Hveem TS; Glaire M; Church DN; Kerr DJ; Yang L; Danielsen HE
    EBioMedicine; 2021 Sep; 71():103547. PubMed ID: 34479131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
    Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
    Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
    Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
    World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
    Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.
    Chen Y; Shankaran V; Hahn EE; Haupt EC; Bansal A
    J Manag Care Spec Pharm; 2023 Jun; 29(6):635-646. PubMed ID: 37276035
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer.
    Sonoda H; Yamada T; Matsuda A; Ohta R; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yoshida H
    Eur J Surg Oncol; 2021 Nov; 47(11):2880-2887. PubMed ID: 34103245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer.
    Zhao K; Li Z; Yao S; Wang Y; Wu X; Xu Z; Wu L; Huang Y; Liang C; Liu Z
    EBioMedicine; 2020 Nov; 61():103054. PubMed ID: 33039706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.